会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Therapeutic agent for osteoporosis and diazepine compound
    • 骨质疏松症和二氮杂化合物治疗剂
    • US5593988A
    • 1997-01-14
    • US211572
    • 1994-08-02
    • Tetsuya TaharaMinoru MoriwakiKenji ChibaShunichi ManabeMasanori ShindoTakashi NakagawaTakeshi Nakamura
    • Tetsuya TaharaMinoru MoriwakiKenji ChibaShunichi ManabeMasanori ShindoTakashi NakagawaTakeshi Nakamura
    • C07D487/04C07D495/04C07D495/14C07D498/04C07D498/14C07D498/22C07D513/04C07D513/14A61K31/55
    • C07D487/04C07D495/04C07D495/14C07D513/04C07D513/14
    • A therapeutic agent for osteoporosis, comprising an azepine compound of the formula ##STR1## wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof as an active ingredient, a method for treating osteoporosis comprising administering said compound and a use of said compound for the production of a therapeutic agent for osteoporosis. The compounds of the formula (I) have superior bone resorption-inhibitory activity and act to reduce the increased amount of calcium in blood serum, which is caused by bone resorption. Accordingly, these compounds are usable as pharmaceutical agents to effectively inhibit bone resorption, to prevent decrease of bone mass and to prevent or suppress the increase of calcium amount in blood serum which is caused by the progress of bone resorption, with regard to Paget's disease, hypercalcemia, osteoporosis and so on in which the progress of bone resorption is considered to be deeply associated with the symptom, and to the symptoms of progressing bone resorption (development into osteoporosis) along with inflammatory joint diseases such as rheumatoid arthritis.
    • PCT No.PCT / JP92 / 01325 Sec。 371日期1994年8月2日 102(e)日期1994年8月2日PCT提交1992年10月12日PCT公布。 公开号WO93 / 07129 日期:1993年04月15日,一种用于骨质疏松症的治疗剂,其包含式(I)的吖庚因化合物,其中每个符号如说明书中所定义,或其药学上可接受的盐作为活性成分,治疗骨质疏松症的方法 包括施用所述化合物和所述化合物用于产生骨质疏松症治疗剂的用途。 式(I)的化合物具有优异的骨吸收抑制活性,并且用于减少由骨吸收引起的血清中钙的增加量。 因此,这些化合物可用作药物,以有效抑制骨吸收,防止骨质量的降低,防止或抑制由于骨吸收进程引起的血液中钙量的增加,关于佩吉特氏病, 高钙血症,骨质疏松症等,其中骨吸收的进展被认为与症状密切相关,以及骨吸收进展(发展为骨质疏松症)以及类风湿性关节炎等炎症性关节疾病的症状。
    • 4. 发明授权
    • Oxazinone derivative
    • 恶嗪酮衍生物
    • US5332734A
    • 1994-07-26
    • US956029
    • 1992-12-10
    • Koji KobayashiShunichi ManabeYoshihiro WatanabeKazuhide HayakawaItsuo Uchida
    • Koji KobayashiShunichi ManabeYoshihiro WatanabeKazuhide HayakawaItsuo Uchida
    • C07D265/22C07D413/12C07D417/12C07D471/04C07D239/95A61K31/535A61K31/54C07D239/72
    • C07D265/22C07D413/10C07D417/12C07D471/04
    • Disclosed is a novel oxazinone derivative represented by formula (I) given below or a pharmaceutically acceptable acid-addition salt thereof, which is useful as an anti-inflammatory agent, an agent for suppressing neutrophil infiltration and as a serine protease inhibitor: ##STR1## where A includes, for example, ##STR2## in which W is --O--, --S--, --CH.dbd.CH-- or --NR.sup.9 -- or means that (CH.sub.2).sub.n is directly bonded to (CH.sub.2).sub.n,V.sup.2 is .dbd.CR.sup.12 -- or .dbd.N--, andD is 5 to 7-membered carbon ring or hetero ring;X is --O--, --S--, --CO--, or --NR.sup.15 or means that A is directly bonded to (CH.sub.2).sub.l ;Y is --O--, --CH.dbd.CH-- or --NR.sup.16 -- or means that (CH.sub.2).sub.l is directly bonded to Z;Z is --CH.sub.2 -- or --CO--; andl is an integer of 0 to 4.Further, R and R.sup.1 to R.sup.16 are hydrogen atom, lower alkyl group, etc.
    • PCT No.PCT / JP92 / 00444 Sec。 371日期:1992年12月10日 102(e)日期1992年12月10日PCT提交1992年4月9日PCT公布。 出版物WO92 / 18488 日期:1992年10月29日。公开是由下述式(I)表示的新型恶嗪酮衍生物或其药学上可接受的酸加成盐,其可用作抗炎剂,抑制嗜中性粒细胞浸润的药剂 丝氨酸蛋白酶抑制剂:其中A包括例如其中W是-O - , - S - , - CH = CH-或-NR 9 - 的,或意味着(CH 2)n直接 键合到(CH 2)n,V 2是= CR 12 - 或= N-,D是5至7元碳环或杂环; X是-O - , - S - , - CO-或-NR 15或意指A直接键合到(CH 2)l; Y是-O - , - CH = CH-或-NR 16 - 或意指(CH 2)l直接键合到Z上; Z是-CH 2 - 或-CO-; l为0〜4的整数。另外,R和R 1〜R 16为氢原子,低级烷基等。
    • 5. 发明授权
    • Switch for power windows
    • 切换电源窗口
    • US4584546A
    • 1986-04-22
    • US730187
    • 1985-05-03
    • Masaichi HattoriShigeo HaraShunichi Manabe
    • Masaichi HattoriShigeo HaraShunichi Manabe
    • H01H23/02B60J1/17H01H3/50H01H23/00H01H23/12H01H23/24H01H3/00H01H21/60
    • H01H23/00H01H23/12H01H3/503E05F15/00E05Y2400/854E05Y2400/86E05Y2900/55H01H2300/01
    • A switch to be used for a power window of an automobile or the like is disclosed. It has a switch body. A knob is rotatably axially supported by the switch body. The knob has an accommodating chamber in its inside. A presser is accommodated within the chamber and biased downward by a spring. A pair of contact blades are positioned under the presser. Each of the contact blades is formed at its central portion with a V-shaped portion and inclined surfaces extending toward the right and left directions. The inclined surfaces are further extended to form contact portions. There is formed with a step between the inclined surfaces and the contact portions, so that a first step of operation and a second step of operation of the knob can be made without mistake. Stationary contacts are positioned corresponding to the contact portions. It also has a pair of contact holders. Each of the holders has a supporting piece folded upward from its one side. The supporting pieces contact the under surfaces of the inclined surfaces. A two way solenoid is connected to the knob to attract it in the both directions.
    • 公开了一种用于汽车等的动力窗的开关。 它有一个开关体。 旋钮由开关主体可旋转地轴向支撑。 旋钮在其内部具有容纳室。 压力机容纳在腔室内并被弹簧向下偏压。 一对接触片位于压脚下方。 每个接触片在其中心部分处形成有V形部分和朝向左右方向延伸的倾斜表面。 倾斜表面进一步延伸以形成接触部分。 在倾斜表面和接触部分之间形成有台阶,从而可以毫无错误地进行操作的第一步骤和操作的第二步骤。 固定触点对应于接触部分定位。 它还有一对接触支架。 每个保持器具有从其一侧向上折叠的支撑件。 支撑件接触倾斜表面的下表面。 双向螺线管连接到旋钮以在两个方向上吸引它。